David Fleischer
Concepts (469)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peanut Hypersensitivity | 58 | 2025 | 146 | 14.450 |
Why?
| | Food Hypersensitivity | 52 | 2025 | 183 | 10.460 |
Why?
| | Arachis | 45 | 2025 | 112 | 9.490 |
Why?
| | Allergens | 58 | 2025 | 407 | 8.550 |
Why?
| | Desensitization, Immunologic | 31 | 2025 | 94 | 6.340 |
Why?
| | Infant Nutritional Physiological Phenomena | 12 | 2025 | 144 | 2.960 |
Why?
| | Anaphylaxis | 13 | 2025 | 105 | 2.730 |
Why?
| | Immunoglobulin E | 33 | 2025 | 341 | 2.320 |
Why?
| | Diet | 18 | 2024 | 1273 | 2.310 |
Why?
| | Dermatitis, Atopic | 15 | 2025 | 328 | 2.000 |
Why?
| | Milk Hypersensitivity | 8 | 2024 | 19 | 1.610 |
Why?
| | Transdermal Patch | 3 | 2020 | 14 | 1.470 |
Why?
| | Eosinophilic Esophagitis | 10 | 2021 | 325 | 1.450 |
Why?
| | Epinephrine | 5 | 2025 | 139 | 1.400 |
Why?
| | Skin Tests | 20 | 2025 | 101 | 1.390 |
Why?
| | Plant Proteins | 4 | 2025 | 114 | 1.180 |
Why?
| | Esophagoscopy | 13 | 2022 | 209 | 1.160 |
Why?
| | Primary Prevention | 5 | 2022 | 196 | 1.140 |
Why?
| | Immunotherapy | 9 | 2024 | 640 | 1.130 |
Why?
| | Hypersensitivity | 4 | 2025 | 257 | 1.070 |
Why?
| | Infant | 47 | 2025 | 9442 | 1.070 |
Why?
| | Antigens, Plant | 7 | 2025 | 54 | 1.070 |
Why?
| | Egg Hypersensitivity | 11 | 2019 | 27 | 0.980 |
Why?
| | Humans | 171 | 2025 | 136783 | 0.970 |
Why?
| | Administration, Cutaneous | 11 | 2025 | 128 | 0.960 |
Why?
| | Gastrointestinal Diseases | 9 | 2019 | 209 | 0.950 |
Why?
| | Infant Formula | 4 | 2023 | 75 | 0.950 |
Why?
| | Child | 60 | 2025 | 21968 | 0.930 |
Why?
| | Child, Preschool | 39 | 2025 | 11069 | 0.900 |
Why?
| | Nut Hypersensitivity | 3 | 2010 | 5 | 0.870 |
Why?
| | Noncommunicable Diseases | 1 | 2023 | 18 | 0.840 |
Why?
| | Breast Feeding | 8 | 2023 | 439 | 0.830 |
Why?
| | Protein Hydrolysates | 3 | 2018 | 6 | 0.790 |
Why?
| | Eczema | 10 | 2022 | 69 | 0.760 |
Why?
| | Anti-Allergic Agents | 5 | 2024 | 46 | 0.760 |
Why?
| | Hypersensitivity, Immediate | 3 | 2023 | 44 | 0.750 |
Why?
| | Endoscopy, Gastrointestinal | 7 | 2022 | 227 | 0.730 |
Why?
| | Immune Tolerance | 9 | 2023 | 362 | 0.700 |
Why?
| | Asthma | 9 | 2025 | 2290 | 0.640 |
Why?
| | Esophageal Stenosis | 6 | 2015 | 54 | 0.640 |
Why?
| | Esophageal Neoplasms | 10 | 2022 | 324 | 0.630 |
Why?
| | Double-Blind Method | 15 | 2025 | 1981 | 0.630 |
Why?
| | Female | 76 | 2025 | 72840 | 0.620 |
Why?
| | Schools | 4 | 2021 | 462 | 0.600 |
Why?
| | Omalizumab | 3 | 2024 | 51 | 0.550 |
Why?
| | Male | 64 | 2025 | 67361 | 0.530 |
Why?
| | Gastroenterology | 2 | 2015 | 181 | 0.500 |
Why?
| | Eosinophilia | 4 | 2013 | 218 | 0.500 |
Why?
| | Practice Guidelines as Topic | 10 | 2024 | 1568 | 0.490 |
Why?
| | Administration, Oral | 9 | 2022 | 808 | 0.490 |
Why?
| | Pneumonia, Viral | 4 | 2020 | 368 | 0.470 |
Why?
| | Nasal Sprays | 2 | 2025 | 5 | 0.470 |
Why?
| | Coronavirus Infections | 4 | 2020 | 359 | 0.470 |
Why?
| | Lye | 1 | 2014 | 1 | 0.450 |
Why?
| | Caustics | 1 | 2014 | 7 | 0.450 |
Why?
| | Dilatation | 2 | 2014 | 65 | 0.450 |
Why?
| | Endosonography | 1 | 2015 | 156 | 0.440 |
Why?
| | Burns, Chemical | 1 | 2014 | 32 | 0.440 |
Why?
| | Adolescent | 25 | 2025 | 21463 | 0.430 |
Why?
| | Barrett Esophagus | 3 | 2022 | 149 | 0.420 |
Why?
| | Feeding Behavior | 3 | 2019 | 648 | 0.420 |
Why?
| | Betacoronavirus | 3 | 2020 | 267 | 0.410 |
Why?
| | Food | 5 | 2024 | 159 | 0.390 |
Why?
| | Pandemics | 5 | 2020 | 1619 | 0.390 |
Why?
| | Environmental Exposure | 1 | 2017 | 576 | 0.380 |
Why?
| | Gastrointestinal Hemorrhage | 4 | 2007 | 132 | 0.370 |
Why?
| | Cattle | 4 | 2024 | 981 | 0.360 |
Why?
| | Infant Food | 2 | 2023 | 65 | 0.350 |
Why?
| | Allergy and Immunology | 3 | 2020 | 43 | 0.350 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2020 | 1455 | 0.350 |
Why?
| | Consensus | 7 | 2024 | 679 | 0.340 |
Why?
| | Esophagus | 8 | 2019 | 255 | 0.340 |
Why?
| | Treatment Outcome | 13 | 2025 | 10764 | 0.340 |
Why?
| | United States | 24 | 2024 | 14660 | 0.330 |
Why?
| | Milk Proteins | 3 | 2024 | 34 | 0.330 |
Why?
| | Adenocarcinoma | 5 | 2022 | 936 | 0.330 |
Why?
| | Allergists | 3 | 2020 | 12 | 0.330 |
Why?
| | Endoscopy | 7 | 2018 | 316 | 0.320 |
Why?
| | Virtual Reality | 2 | 2021 | 61 | 0.310 |
Why?
| | Risk | 5 | 2018 | 904 | 0.300 |
Why?
| | Young Adult | 13 | 2025 | 13126 | 0.290 |
Why?
| | Capsule Endoscopy | 1 | 2007 | 18 | 0.280 |
Why?
| | Intestinal Diseases | 1 | 2007 | 41 | 0.280 |
Why?
| | Adult | 26 | 2025 | 37616 | 0.280 |
Why?
| | Enterocolitis | 2 | 2020 | 17 | 0.270 |
Why?
| | Colonoscopy | 4 | 2014 | 247 | 0.270 |
Why?
| | Severity of Illness Index | 6 | 2019 | 2831 | 0.270 |
Why?
| | Brazil | 2 | 2023 | 167 | 0.250 |
Why?
| | Time Factors | 7 | 2020 | 6792 | 0.250 |
Why?
| | Adrenal Cortex Hormones | 3 | 2017 | 551 | 0.250 |
Why?
| | Capsules | 2 | 2005 | 38 | 0.250 |
Why?
| | Rhinitis, Allergic | 3 | 2022 | 38 | 0.250 |
Why?
| | National Institute of Allergy and Infectious Diseases (U.S.) | 7 | 2019 | 21 | 0.240 |
Why?
| | Pregnancy | 9 | 2024 | 6731 | 0.230 |
Why?
| | Administration, Sublingual | 3 | 2016 | 11 | 0.230 |
Why?
| | Immunomodulation | 2 | 2018 | 97 | 0.220 |
Why?
| | Canada | 3 | 2020 | 420 | 0.220 |
Why?
| | Age Factors | 7 | 2018 | 3290 | 0.220 |
Why?
| | Gastrointestinal Neoplasms | 3 | 2000 | 77 | 0.220 |
Why?
| | Follow-Up Studies | 7 | 2020 | 5115 | 0.220 |
Why?
| | Healthy Volunteers | 2 | 2024 | 197 | 0.210 |
Why?
| | Diagnostic Imaging | 2 | 2006 | 331 | 0.210 |
Why?
| | Catheter Ablation | 2 | 2019 | 349 | 0.210 |
Why?
| | Constipation | 1 | 2024 | 94 | 0.200 |
Why?
| | Eosinophils | 2 | 2018 | 331 | 0.200 |
Why?
| | Laser Therapy | 5 | 1985 | 130 | 0.200 |
Why?
| | Intestinal Mucosa | 2 | 2015 | 620 | 0.200 |
Why?
| | Cross-Over Studies | 1 | 2024 | 560 | 0.190 |
Why?
| | Middle Aged | 22 | 2025 | 33200 | 0.190 |
Why?
| | Food Analysis | 1 | 2022 | 26 | 0.190 |
Why?
| | Point-of-Care Testing | 1 | 2022 | 32 | 0.190 |
Why?
| | Gastroesophageal Reflux | 2 | 2022 | 234 | 0.180 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 2030 | 0.180 |
Why?
| | Animals | 13 | 2024 | 36768 | 0.180 |
Why?
| | Child Day Care Centers | 1 | 2021 | 34 | 0.180 |
Why?
| | Milk | 3 | 2018 | 124 | 0.180 |
Why?
| | Dietary Exposure | 1 | 2020 | 6 | 0.180 |
Why?
| | Aptamers, Nucleotide | 1 | 2022 | 83 | 0.170 |
Why?
| | Restaurants | 1 | 2020 | 25 | 0.170 |
Why?
| | Diet Therapy | 2 | 2017 | 34 | 0.170 |
Why?
| | Infusions, Subcutaneous | 1 | 2020 | 23 | 0.170 |
Why?
| | Eggs | 2 | 2018 | 25 | 0.170 |
Why?
| | Deglutition Disorders | 2 | 2019 | 143 | 0.170 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2020 | 105 | 0.170 |
Why?
| | Inservice Training | 1 | 2020 | 113 | 0.160 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2024 | 607 | 0.160 |
Why?
| | Europe | 2 | 2022 | 414 | 0.160 |
Why?
| | Respiratory Tract Infections | 1 | 2024 | 396 | 0.160 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1483 | 0.160 |
Why?
| | Immunization | 3 | 2017 | 410 | 0.160 |
Why?
| | Quality of Life | 6 | 2022 | 2868 | 0.150 |
Why?
| | Prevalence | 4 | 2024 | 2712 | 0.150 |
Why?
| | Multiphasic Screening | 1 | 2018 | 1 | 0.150 |
Why?
| | Meta-Analysis as Topic | 2 | 2016 | 172 | 0.150 |
Why?
| | United Kingdom | 4 | 2020 | 315 | 0.150 |
Why?
| | Confidence Intervals | 1 | 2019 | 328 | 0.150 |
Why?
| | Population Groups | 1 | 2018 | 62 | 0.140 |
Why?
| | Ambulatory Care Facilities | 1 | 2020 | 230 | 0.140 |
Why?
| | Food, Genetically Modified | 1 | 2017 | 2 | 0.140 |
Why?
| | Coal Tar | 1 | 2017 | 3 | 0.140 |
Why?
| | Health Promotion | 1 | 2024 | 736 | 0.140 |
Why?
| | Skin Cream | 1 | 2017 | 11 | 0.140 |
Why?
| | Keratolytic Agents | 1 | 2017 | 5 | 0.140 |
Why?
| | Blood Pressure | 1 | 2025 | 1772 | 0.140 |
Why?
| | Phosphodiesterase 4 Inhibitors | 1 | 2017 | 5 | 0.140 |
Why?
| | Emollients | 1 | 2017 | 10 | 0.140 |
Why?
| | Plants, Genetically Modified | 1 | 2017 | 16 | 0.140 |
Why?
| | Baths | 1 | 2017 | 14 | 0.140 |
Why?
| | Histamine Antagonists | 1 | 2017 | 21 | 0.140 |
Why?
| | Monitoring, Physiologic | 2 | 1990 | 267 | 0.140 |
Why?
| | Clothing | 1 | 2017 | 22 | 0.140 |
Why?
| | Crops, Agricultural | 1 | 2017 | 31 | 0.140 |
Why?
| | Calcineurin Inhibitors | 1 | 2017 | 72 | 0.140 |
Why?
| | School Health Services | 1 | 2020 | 239 | 0.140 |
Why?
| | Telemedicine | 3 | 2020 | 847 | 0.130 |
Why?
| | Mothers | 1 | 2023 | 752 | 0.130 |
Why?
| | Risk Assessment | 4 | 2019 | 3429 | 0.130 |
Why?
| | Nutritionists | 1 | 2016 | 19 | 0.130 |
Why?
| | Prognosis | 2 | 2020 | 4018 | 0.130 |
Why?
| | Palliative Care | 4 | 2010 | 743 | 0.130 |
Why?
| | Education, Medical, Continuing | 1 | 2017 | 125 | 0.130 |
Why?
| | Basophils | 2 | 2015 | 73 | 0.130 |
Why?
| | Eating | 1 | 2019 | 378 | 0.130 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 107 | 0.130 |
Why?
| | Kidney Transplantation | 1 | 2022 | 700 | 0.120 |
Why?
| | Bottle Feeding | 1 | 2016 | 21 | 0.120 |
Why?
| | Infant, Newborn | 6 | 2024 | 6046 | 0.120 |
Why?
| | Surveys and Questionnaires | 7 | 2024 | 5749 | 0.120 |
Why?
| | Indonesia | 1 | 2015 | 23 | 0.120 |
Why?
| | Health Care Reform | 2 | 1994 | 102 | 0.120 |
Why?
| | Decision Support Techniques | 1 | 2020 | 418 | 0.120 |
Why?
| | Nutritional Requirements | 1 | 2016 | 77 | 0.120 |
Why?
| | Biological Products | 1 | 2018 | 215 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2022 | 1162 | 0.120 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2015 | 34 | 0.120 |
Why?
| | Sublingual Immunotherapy | 1 | 2015 | 5 | 0.120 |
Why?
| | Probiotics | 1 | 2015 | 53 | 0.120 |
Why?
| | Aging | 1 | 2005 | 1861 | 0.120 |
Why?
| | Carcinoma in Situ | 1 | 2015 | 49 | 0.120 |
Why?
| | Fluticasone | 1 | 2015 | 90 | 0.110 |
Why?
| | Guideline Adherence | 1 | 2019 | 543 | 0.110 |
Why?
| | History, 21st Century | 1 | 2015 | 211 | 0.110 |
Why?
| | History, 20th Century | 1 | 2015 | 323 | 0.110 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2015 | 682 | 0.110 |
Why?
| | Coloring Agents | 2 | 2015 | 86 | 0.110 |
Why?
| | Biopsy | 5 | 2019 | 1126 | 0.110 |
Why?
| | Anti-Bacterial Agents | 3 | 2017 | 1799 | 0.110 |
Why?
| | Wrist Injuries | 1 | 2014 | 23 | 0.110 |
Why?
| | Caregivers | 2 | 2020 | 873 | 0.110 |
Why?
| | Premedication | 3 | 1990 | 44 | 0.110 |
Why?
| | Risk Factors | 7 | 2019 | 10331 | 0.110 |
Why?
| | Prospective Studies | 8 | 2019 | 7583 | 0.100 |
Why?
| | Cumulative Trauma Disorders | 1 | 2014 | 42 | 0.100 |
Why?
| | Wrist Joint | 1 | 2014 | 61 | 0.100 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 584 | 0.100 |
Why?
| | Physicians | 2 | 2020 | 897 | 0.100 |
Why?
| | Occupational Injuries | 1 | 2014 | 44 | 0.100 |
Why?
| | Family | 2 | 2015 | 666 | 0.100 |
Why?
| | Information Systems | 1 | 1993 | 60 | 0.100 |
Why?
| | Posture | 2 | 2014 | 186 | 0.100 |
Why?
| | Epitopes | 2 | 2025 | 480 | 0.100 |
Why?
| | Patient Education as Topic | 2 | 2015 | 760 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2020 | 939 | 0.100 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 738 | 0.100 |
Why?
| | Societies, Medical | 2 | 1994 | 820 | 0.100 |
Why?
| | Sympathomimetics | 1 | 2012 | 21 | 0.100 |
Why?
| | Mucositis | 1 | 2012 | 19 | 0.100 |
Why?
| | Disease Progression | 5 | 2019 | 2750 | 0.100 |
Why?
| | Poisson Distribution | 1 | 2012 | 72 | 0.100 |
Why?
| | Recurrence | 3 | 2004 | 1058 | 0.100 |
Why?
| | Pregnenediones | 1 | 2012 | 19 | 0.100 |
Why?
| | Oximetry | 2 | 1990 | 95 | 0.090 |
Why?
| | Patient Compliance | 2 | 2016 | 576 | 0.090 |
Why?
| | Health Surveys | 2 | 2012 | 517 | 0.090 |
Why?
| | Disease Management | 3 | 2024 | 623 | 0.090 |
Why?
| | Cohort Studies | 5 | 2022 | 5718 | 0.090 |
Why?
| | Child Development | 1 | 2016 | 471 | 0.090 |
Why?
| | Self Care | 1 | 2014 | 375 | 0.090 |
Why?
| | Bacterial Proteins | 1 | 2017 | 895 | 0.090 |
Why?
| | Patient Satisfaction | 1 | 2015 | 650 | 0.090 |
Why?
| | Stents | 3 | 2000 | 528 | 0.090 |
Why?
| | Symptom Assessment | 1 | 2012 | 125 | 0.090 |
Why?
| | Biomarkers | 2 | 2020 | 4158 | 0.090 |
Why?
| | Feeding and Eating Disorders of Childhood | 1 | 2010 | 7 | 0.090 |
Why?
| | Curriculum | 1 | 2017 | 979 | 0.090 |
Why?
| | Metaplasia | 2 | 2022 | 60 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1294 | 0.080 |
Why?
| | Immunoassay | 1 | 2010 | 113 | 0.080 |
Why?
| | Cathartics | 1 | 1990 | 15 | 0.080 |
Why?
| | Health Policy | 1 | 1993 | 387 | 0.080 |
Why?
| | Citrates | 1 | 1990 | 44 | 0.080 |
Why?
| | Flavoring Agents | 1 | 1990 | 13 | 0.080 |
Why?
| | Adaptation, Psychological | 1 | 2015 | 651 | 0.080 |
Why?
| | Immunologic Factors | 2 | 2022 | 237 | 0.080 |
Why?
| | Phenotype | 1 | 2018 | 3199 | 0.080 |
Why?
| | Regression Analysis | 1 | 2012 | 1024 | 0.080 |
Why?
| | Duodenoscopy | 1 | 1989 | 7 | 0.080 |
Why?
| | Diet Surveys | 2 | 2024 | 95 | 0.080 |
Why?
| | Gastroscopy | 1 | 1989 | 19 | 0.080 |
Why?
| | Epithelial Cells | 2 | 2014 | 1093 | 0.080 |
Why?
| | Food, Formulated | 1 | 2009 | 14 | 0.080 |
Why?
| | Drainage | 1 | 2010 | 168 | 0.080 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2013 | 351 | 0.080 |
Why?
| | Retrospective Studies | 6 | 2024 | 15564 | 0.080 |
Why?
| | Lasers | 3 | 1985 | 130 | 0.080 |
Why?
| | Physician-Patient Relations | 1 | 1993 | 544 | 0.080 |
Why?
| | Maternal Exposure | 1 | 2010 | 188 | 0.070 |
Why?
| | Light Coagulation | 1 | 1988 | 8 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1242 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 804 | 0.070 |
Why?
| | Physical Examination | 1 | 2009 | 241 | 0.070 |
Why?
| | Precancerous Conditions | 2 | 2019 | 169 | 0.070 |
Why?
| | Cholestasis | 1 | 2010 | 232 | 0.070 |
Why?
| | Digestive System | 2 | 2002 | 28 | 0.070 |
Why?
| | Hypnotics and Sedatives | 1 | 1989 | 199 | 0.070 |
Why?
| | Feces | 1 | 1990 | 479 | 0.060 |
Why?
| | Aged | 15 | 2019 | 23729 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1428 | 0.060 |
Why?
| | Risk Reduction Behavior | 2 | 2019 | 218 | 0.060 |
Why?
| | Immunologic Tests | 1 | 2005 | 16 | 0.060 |
Why?
| | Remission, Spontaneous | 1 | 2005 | 40 | 0.060 |
Why?
| | Comorbidity | 2 | 2025 | 1611 | 0.060 |
Why?
| | Sepsis | 2 | 1989 | 611 | 0.060 |
Why?
| | Equipment Safety | 1 | 2005 | 37 | 0.060 |
Why?
| | Equipment Design | 2 | 2005 | 522 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3272 | 0.060 |
Why?
| | Anti-Inflammatory Agents | 1 | 2009 | 495 | 0.060 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1942 | 0.060 |
Why?
| | Dietetics | 2 | 2017 | 27 | 0.060 |
Why?
| | Esophageal and Gastric Varices | 1 | 1985 | 40 | 0.060 |
Why?
| | Administration, Intranasal | 1 | 2024 | 90 | 0.060 |
Why?
| | Procainamide | 1 | 1984 | 5 | 0.060 |
Why?
| | Immunoglobulin G | 3 | 2014 | 886 | 0.060 |
Why?
| | Hyperplasia | 2 | 2022 | 175 | 0.060 |
Why?
| | Injections, Intramuscular | 1 | 2024 | 126 | 0.050 |
Why?
| | Nutrition Assessment | 1 | 2024 | 90 | 0.050 |
Why?
| | Pollen | 1 | 2023 | 21 | 0.050 |
Why?
| | Therapeutic Irrigation | 1 | 1984 | 78 | 0.050 |
Why?
| | Intestinal Absorption | 1 | 1984 | 101 | 0.050 |
Why?
| | Excipients | 1 | 2023 | 54 | 0.050 |
Why?
| | Turkey | 1 | 2022 | 22 | 0.050 |
Why?
| | Digestive System Diseases | 1 | 2002 | 26 | 0.050 |
Why?
| | Delphi Technique | 1 | 2024 | 273 | 0.050 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2024 | 175 | 0.050 |
Why?
| | Vitamins | 1 | 2024 | 177 | 0.050 |
Why?
| | Immunity | 1 | 2023 | 144 | 0.050 |
Why?
| | Software | 1 | 2007 | 663 | 0.050 |
Why?
| | Metals | 2 | 2000 | 137 | 0.050 |
Why?
| | Hemoglobinuria, Paroxysmal | 1 | 2002 | 6 | 0.050 |
Why?
| | HLA Antigens | 1 | 2022 | 237 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4279 | 0.040 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2020 | 28 | 0.040 |
Why?
| | Injections | 1 | 2021 | 181 | 0.040 |
Why?
| | Educational Personnel | 1 | 2020 | 12 | 0.040 |
Why?
| | Japan | 1 | 2000 | 116 | 0.040 |
Why?
| | Terbutaline | 1 | 2020 | 8 | 0.040 |
Why?
| | Respiratory Sounds | 1 | 2021 | 123 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2002 | 211 | 0.040 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2000 | 18 | 0.040 |
Why?
| | Cholestasis, Intrahepatic | 1 | 2000 | 39 | 0.040 |
Why?
| | China | 1 | 2000 | 217 | 0.040 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2020 | 69 | 0.040 |
Why?
| | Albuterol | 1 | 2020 | 110 | 0.040 |
Why?
| | Food Contamination | 1 | 2019 | 48 | 0.040 |
Why?
| | Bronchodilator Agents | 1 | 2021 | 248 | 0.040 |
Why?
| | Interprofessional Relations | 2 | 1994 | 280 | 0.040 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2018 | 82 | 0.040 |
Why?
| | Medical History Taking | 1 | 2019 | 119 | 0.040 |
Why?
| | Esophagogastric Junction | 1 | 2019 | 51 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 2 | 2012 | 556 | 0.040 |
Why?
| | Ischemia | 1 | 2002 | 407 | 0.040 |
Why?
| | Intestines | 1 | 2002 | 359 | 0.040 |
Why?
| | Health Planning Guidelines | 1 | 2018 | 25 | 0.040 |
Why?
| | New Zealand | 1 | 2018 | 55 | 0.040 |
Why?
| | Efferent Pathways | 1 | 1998 | 19 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2417 | 0.040 |
Why?
| | Psychometrics | 1 | 2022 | 721 | 0.040 |
Why?
| | Food Labeling | 1 | 2017 | 14 | 0.040 |
Why?
| | Hydrolysis | 1 | 2018 | 191 | 0.040 |
Why?
| | Locus Coeruleus | 1 | 1998 | 23 | 0.040 |
Why?
| | Markov Chains | 1 | 2018 | 122 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2021 | 362 | 0.040 |
Why?
| | Cross Reactions | 1 | 2017 | 133 | 0.040 |
Why?
| | Early Medical Intervention | 1 | 2018 | 57 | 0.040 |
Why?
| | Immune Sera | 1 | 2017 | 88 | 0.030 |
Why?
| | Skin Irritancy Tests | 1 | 2017 | 3 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2019 | 136 | 0.030 |
Why?
| | RNA, Viral | 1 | 2021 | 651 | 0.030 |
Why?
| | Metiamide | 1 | 1977 | 1 | 0.030 |
Why?
| | Thiourea | 1 | 1977 | 40 | 0.030 |
Why?
| | Agranulocytosis | 1 | 1977 | 30 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2019 | 563 | 0.030 |
Why?
| | Guanidines | 1 | 1977 | 40 | 0.030 |
Why?
| | Australia | 1 | 2018 | 314 | 0.030 |
Why?
| | Societies, Scientific | 1 | 2017 | 51 | 0.030 |
Why?
| | Norepinephrine | 1 | 1998 | 204 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2017 | 189 | 0.030 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2016 | 28 | 0.030 |
Why?
| | Uncertainty | 1 | 2017 | 128 | 0.030 |
Why?
| | Nutritional Sciences | 1 | 2017 | 42 | 0.030 |
Why?
| | Protective Factors | 1 | 2017 | 93 | 0.030 |
Why?
| | Transgenes | 1 | 2017 | 179 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2017 | 192 | 0.030 |
Why?
| | Probability | 1 | 2017 | 309 | 0.030 |
Why?
| | Drug Dosage Calculations | 1 | 2016 | 23 | 0.030 |
Why?
| | Incidence | 2 | 2019 | 2788 | 0.030 |
Why?
| | Injections, Subcutaneous | 1 | 2016 | 154 | 0.030 |
Why?
| | Imidazoles | 1 | 1977 | 239 | 0.030 |
Why?
| | Protein Binding | 1 | 2022 | 2223 | 0.030 |
Why?
| | Iodides | 1 | 2015 | 8 | 0.030 |
Why?
| | Radio Waves | 1 | 2015 | 18 | 0.030 |
Why?
| | Mouth | 1 | 2015 | 86 | 0.030 |
Why?
| | Mass Screening | 2 | 2019 | 1262 | 0.030 |
Why?
| | Mice | 1 | 2011 | 17731 | 0.030 |
Why?
| | Endoscopes | 2 | 1985 | 17 | 0.030 |
Why?
| | Calpain | 1 | 2014 | 59 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1998 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2012 | 2847 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 306 | 0.030 |
Why?
| | Synapses | 1 | 1998 | 425 | 0.030 |
Why?
| | Treatment Failure | 1 | 2015 | 353 | 0.030 |
Why?
| | Organ Specificity | 1 | 2014 | 304 | 0.030 |
Why?
| | Steroids | 1 | 2014 | 167 | 0.030 |
Why?
| | Population Surveillance | 1 | 2017 | 470 | 0.030 |
Why?
| | Interleukin-13 | 1 | 2014 | 149 | 0.030 |
Why?
| | Public Opinion | 1 | 1993 | 65 | 0.030 |
Why?
| | Eosinophil Granule Proteins | 1 | 2012 | 21 | 0.020 |
Why?
| | Aged, 80 and over | 5 | 2010 | 7569 | 0.020 |
Why?
| | Lysophospholipase | 1 | 2012 | 10 | 0.020 |
Why?
| | Haplotypes | 1 | 2014 | 490 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1055 | 0.020 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2012 | 20 | 0.020 |
Why?
| | Liver Transplantation | 1 | 2000 | 871 | 0.020 |
Why?
| | Forecasting | 1 | 1994 | 384 | 0.020 |
Why?
| | Biomedical Research | 1 | 2018 | 689 | 0.020 |
Why?
| | Survival Rate | 2 | 2010 | 1969 | 0.020 |
Why?
| | Movement | 1 | 2014 | 272 | 0.020 |
Why?
| | Mucous Membrane | 1 | 2012 | 125 | 0.020 |
Why?
| | Range of Motion, Articular | 1 | 2014 | 390 | 0.020 |
Why?
| | Models, Genetic | 1 | 2014 | 605 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 806 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 843 | 0.020 |
Why?
| | Abdominal Pain | 2 | 2002 | 145 | 0.020 |
Why?
| | Specimen Handling | 1 | 2012 | 178 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2022 | 2624 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 3953 | 0.020 |
Why?
| | Age of Onset | 1 | 2012 | 518 | 0.020 |
Why?
| | Joint Commission on Accreditation of Healthcare Organizations | 1 | 1990 | 9 | 0.020 |
Why?
| | Professional Role | 1 | 2012 | 165 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2014 | 808 | 0.020 |
Why?
| | Glycoproteins | 1 | 2012 | 344 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2012 | 687 | 0.020 |
Why?
| | Gallbladder Neoplasms | 1 | 2010 | 23 | 0.020 |
Why?
| | Midazolam | 1 | 1990 | 56 | 0.020 |
Why?
| | Citric Acid | 1 | 1990 | 33 | 0.020 |
Why?
| | Endocarditis, Bacterial | 1 | 1989 | 42 | 0.020 |
Why?
| | Computer Simulation | 1 | 2014 | 973 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 217 | 0.020 |
Why?
| | Health Status | 1 | 2014 | 781 | 0.020 |
Why?
| | Genetic Variation | 1 | 2014 | 985 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1919 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 5417 | 0.020 |
Why?
| | Anesthesiology | 1 | 1990 | 85 | 0.020 |
Why?
| | Cholangiocarcinoma | 1 | 2010 | 104 | 0.020 |
Why?
| | Pancreatic Neoplasms | 2 | 2010 | 931 | 0.020 |
Why?
| | Neurons | 1 | 1998 | 1583 | 0.020 |
Why?
| | Bile Duct Neoplasms | 1 | 2010 | 123 | 0.020 |
Why?
| | Pneumoperitoneum | 1 | 1988 | 12 | 0.020 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 1988 | 20 | 0.020 |
Why?
| | Social Support | 1 | 2012 | 615 | 0.020 |
Why?
| | Anxiety | 1 | 2015 | 1032 | 0.020 |
Why?
| | Electrocoagulation | 1 | 1987 | 40 | 0.020 |
Why?
| | Cell Movement | 1 | 2012 | 969 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2014 | 1434 | 0.020 |
Why?
| | Gastrostomy | 1 | 1988 | 112 | 0.020 |
Why?
| | Electrocardiography | 1 | 1990 | 628 | 0.020 |
Why?
| | Pediatrics | 1 | 2015 | 1112 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2015 | 1098 | 0.020 |
Why?
| | Parents | 1 | 2015 | 1355 | 0.020 |
Why?
| | Duodenal Ulcer | 1 | 1985 | 13 | 0.020 |
Why?
| | Drug Design | 1 | 2006 | 166 | 0.010 |
Why?
| | Genetic Markers | 1 | 2006 | 344 | 0.010 |
Why?
| | Hemostatic Techniques | 1 | 1985 | 47 | 0.010 |
Why?
| | Arteriovenous Malformations | 1 | 1985 | 27 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1985 | 177 | 0.010 |
Why?
| | Health Services Accessibility | 1 | 2012 | 976 | 0.010 |
Why?
| | Random Allocation | 1 | 1985 | 353 | 0.010 |
Why?
| | Electrolytes | 1 | 1984 | 58 | 0.010 |
Why?
| | Stomach Neoplasms | 1 | 1985 | 124 | 0.010 |
Why?
| | Quinidine | 1 | 1983 | 6 | 0.010 |
Why?
| | Streptococcal Infections | 1 | 1985 | 151 | 0.010 |
Why?
| | Tablets | 1 | 1983 | 36 | 0.010 |
Why?
| | Cholelithiasis | 1 | 2002 | 37 | 0.010 |
Why?
| | Gallstones | 1 | 2002 | 31 | 0.010 |
Why?
| | Biliary Tract Neoplasms | 1 | 2002 | 30 | 0.010 |
Why?
| | Colonic Diseases | 1 | 1982 | 33 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2010 | 792 | 0.010 |
Why?
| | Iran | 1 | 2002 | 42 | 0.010 |
Why?
| | Jejunum | 1 | 2002 | 31 | 0.010 |
Why?
| | Pancreatitis | 1 | 2002 | 132 | 0.010 |
Why?
| | Duodenum | 1 | 2002 | 77 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 189 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2002 | 432 | 0.010 |
Why?
| | Dogs | 1 | 1982 | 409 | 0.010 |
Why?
| | Rectal Neoplasms | 1 | 1982 | 149 | 0.010 |
Why?
| | Age Distribution | 1 | 2002 | 391 | 0.010 |
Why?
| | Sex Distribution | 1 | 2002 | 376 | 0.010 |
Why?
| | Granulation Tissue | 1 | 2000 | 6 | 0.010 |
Why?
| | Foreign-Body Reaction | 1 | 2000 | 31 | 0.010 |
Why?
| | Pruritus | 1 | 2000 | 63 | 0.010 |
Why?
| | Equipment Failure Analysis | 1 | 2000 | 132 | 0.010 |
Why?
| | Acute Disease | 1 | 2002 | 1006 | 0.010 |
Why?
| | Aspirin | 1 | 1983 | 384 | 0.010 |
Why?
| | Axonal Transport | 1 | 1998 | 27 | 0.010 |
Why?
| | Neuropeptides | 1 | 1998 | 74 | 0.010 |
Why?
| | Neurons, Afferent | 1 | 1998 | 97 | 0.010 |
Why?
| | Fibrosis | 1 | 2000 | 551 | 0.010 |
Why?
| | Tracheoesophageal Fistula | 1 | 1997 | 34 | 0.010 |
Why?
| | Biocompatible Materials | 1 | 2000 | 423 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2000 | 1373 | 0.010 |
Why?
| | Brain Mapping | 1 | 1998 | 504 | 0.010 |
Why?
| | False Positive Reactions | 1 | 1988 | 114 | 0.000 |
Why?
| | Peptococcus | 1 | 1985 | 1 | 0.000 |
Why?
| | Radiography | 1 | 1988 | 829 | 0.000 |
Why?
| | Drinking | 1 | 1983 | 42 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1987 | 1043 | 0.000 |
Why?
| | Deglutition | 1 | 1983 | 72 | 0.000 |
Why?
| | Esophagitis | 1 | 1983 | 67 | 0.000 |
Why?
| | Pilot Projects | 1 | 1987 | 1697 | 0.000 |
Why?
|
|
Fleischer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|